These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 23571149)

  • 1. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?
    van Dam L; Korfage IJ; Kuipers EJ; Hol L; van Roon AH; Reijerink JC; van Ballegooijen M; van Leerdam ME
    Eur J Cancer; 2013 Jul; 49(10):2321-30. PubMed ID: 23571149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy.
    Hol L; de Jonge V; van Leerdam ME; van Ballegooijen M; Looman CW; van Vuuren AJ; Reijerink JC; Habbema JD; Essink-Bot ML; Kuipers EJ
    Eur J Cancer; 2010 Jul; 46(11):2059-66. PubMed ID: 20621736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing different strategies for colorectal cancer screening in Italy: predictors of patients' participation.
    Senore C; Armaroli P; Silvani M; Andreoni B; Bisanti L; Marai L; Castiglione G; Grazzini G; Taddei S; Gasperoni S; Giuliani O; Malfitana G; Marutti A; Genta G; Segnan N
    Am J Gastroenterol; 2010 Jan; 105(1):188-98. PubMed ID: 19826409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low priority main reason not to participate in a colorectal cancer screening program with a faecal occult blood test.
    van Rijn AF; van Rossum LG; Deutekom M; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    J Public Health (Oxf); 2008 Dec; 30(4):461-5. PubMed ID: 18716047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer screening behavior in women attending screening mammography: longitudinal trends and predictors.
    Carlos RC; Fendrick AM; Abrahamse PH; Dong Q; Patterson SK; Bernstein SJ
    Womens Health Issues; 2005; 15(6):249-57. PubMed ID: 16325138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening.
    DeBourcy AC; Lichtenberger S; Felton S; Butterfield KT; Ahnen DJ; Denberg TD
    J Gen Intern Med; 2008 Feb; 23(2):169-74. PubMed ID: 18157581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
    Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
    Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Offering people a choice for colorectal cancer screening.
    Senore C; Ederle A; Benazzato L; Arrigoni A; Silvani M; Fantin A; Fracchia M; Armaroli P; Segnan N
    Gut; 2013 May; 62(5):735-40. PubMed ID: 22442162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of previous non-participants cannot fully compensate for lower participation in a second round of FIT-screening.
    Denters MJ; Deutekom M; Bossuyt PM; van Rijn AF; Fockens P; Dekker E
    Cancer Epidemiol; 2013 Jun; 37(3):330-5. PubMed ID: 23403127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for colorectal cancer: sense and sensibilities.
    Van Hal G; Hoeck S; Van Roosbroeck S
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S156-63. PubMed ID: 21943969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for colorectal cancer screening.
    Bretthauer M
    Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):417-25. PubMed ID: 20833346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
    Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferences for colorectal cancer screening techniques and intention to attend: a multi-criteria decision analysis.
    Hummel JM; Steuten LG; Groothuis-Oudshoorn CJ; Mulder N; Ijzerman MJ
    Appl Health Econ Health Policy; 2013 Oct; 11(5):499-507. PubMed ID: 23979875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Would general practitioners support a population-based colorectal cancer screening programme of faecal-occult blood testing?
    Tong S; Hughes K; Oldenburg B; Del Mar C
    Intern Med J; 2004; 34(9-10):532-8. PubMed ID: 15482265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of self-reported history of colorectal cancer screening.
    Khoja S; McGregor SE; Hilsden RJ
    Can Fam Physician; 2007 Jul; 53(7):1192-7. PubMed ID: 17872816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal occult blood testing (FOBT)-based colorectal cancer screening trends and predictors of non-use: findings from the South Australian setting and implications for increasing FOBT uptake.
    Todorov K; Wilson C; Sharplin G; Corsini N
    Aust Health Rev; 2018 Feb; 42(1):45-52. PubMed ID: 28248632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.